breast cancer risk

Reevaluating the Safety and Clinical Implications of Menopausal Hormone Therapy: A Contemporary Perspective

By MedXY 10/30/2026

Menopausal hormone therapy remains the most effective treatment for estrogen deficiency symptoms, with a favorable benefit-risk profile when individualized by age, timing, and formulation. Emerging evidence refines safety perceptions, guiding tailored clinical decisions.

news OB/GYN & Women’s Health Oncology

Reevaluating Menopausal Estrogen Therapy: Implications for Breast Cancer Risk Reduction

By MedXY 08/16/2026

Emerging evidence suggests menopausal estrogen-only therapy post-hysterectomy may reduce breast cancer risk both in general and BRCA mutation populations. Shared decision-making is key when considering therapy and surgical options for benign gynecologic conditions.

news OB/GYN & Women's Health Oncology

Hormonal Contraceptive Progestin Content Strongly Modifies Breast Cancer Risk in Adolescents and Premenopausal Women

By MedXY 11/12/2025

A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute excess risk remains small in women <50 years.